TCTR20210824002已完成不适用
A study evaluating the persistence rate of osteoporosis treatment with anti-osteoporosis drug in patient who had osteoporotic hip fracture
/A0 个研究点目标入组 562 人开始时间: 2021年8月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 562
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 50 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Previous osteoporotic hip fracture patient whom admitted and operated in Siriraj hospital
- •2. Age 50 years old or more
- •3. At least 1 year follow-up period
排除标准
- •1.Pathological hip fracture
- •2.Atypical femoral fracture
- •3.High energy injury
- •4.Inability to communicate
研究者
相似试验
进行中（未招募）
1 期
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864EUCTR2021-000452-19-BGObsEva S.A.400
进行中（未招募）
1 期
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864EUCTR2021-000452-19-PLObsEva S.A.400
进行中（未招募）
1 期
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864EUCTR2021-000452-19-HUObsEva S.A.400
进行中（未招募）
1 期
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864EUCTR2021-000452-19-LVKissei Pharmaceutical Co., Ltd.147
进行中（未招募）
1 期
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2EUCTR2021-000452-19-ROObsEva S.A.400